ArticleScientific reports2025
Probing into 9'-substituted Suzuki-coupled noscapine ionic liquids as potent microtubule targeting anticancer agents with hemoglobin affinity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On a global scale, lung cancer accounts for 18% of all cancer deaths making it the most lethal cancer. To restrain this, there has been continual research in the domain of microtubule-targeting anticancer agents but issues like toxicity, immunosuppression, effective delivery to tumor site, etc. persist to impede their clinical success. Unlike the other existing drugs in this regime; noscapine (a non-opioid alkaloid) is testified to be an intrinsically safer drug with minimal side effects. In this work, we have synthesized and evaluated novel 9'-substituted suzuki-coupled noscapine ionic liquid(s) as effectual anticancer drug(s) against non-small cell (H1299) lung cancer. We have devised a synthetic route (employed suzuki coupling for subsuming the biaryl pharmacophore and combined it with the idea of active pharmaceutical ingredient-based ionic liquids (API-ILs)) to yield the desired API-ILs followed by their characterization using associated analytical techniques like NMR, HRMS, etc. Following this, we have performed SAR analysis of the API-ILs using molecular docking with the target tubulin protein and preliminary in vitro screening against H1299 (non-small cancer) cells to opt for the most promising analogue i.e., [p-NO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.